The TTS-S plaster contains a total of 1.5 mg of scopolamine, which is released in a controlled manner over a 3-day period. The system includes an initial priming dose of 140 micrograms in the adhesive layer to quickly saturate skin binding sites and achieve steady-state blood levels. The remaining scopolamine is released at a constant rate of about 5 micrograms per hour, totaling 0.5 mg over the 3 days. This design ensures effective delivery while minimizing side effects.
Key Points Explained:
-
Total Scopolamine Content:
- The TTS-S plaster contains a reservoir of 1.5 mg of scopolamine. This is the total amount loaded into the plaster, ensuring sufficient drug supply for the intended delivery period.
-
Priming Dose:
- A priming dose of 140 micrograms is incorporated into the adhesive layer. This serves two purposes:
- Saturates binding sites in the skin to prevent initial rapid absorption.
- Accelerates the achievement of steady-state blood levels, ensuring therapeutic effectiveness quickly.
- A priming dose of 140 micrograms is incorporated into the adhesive layer. This serves two purposes:
-
Controlled Release Mechanism:
- The remaining scopolamine (after the priming dose) is released at a constant rate of approximately 5 micrograms per hour. This controlled release:
- Ensures a consistent drug level in the bloodstream.
- Minimizes fluctuations that could lead to side effects or reduced efficacy.
- The remaining scopolamine (after the priming dose) is released at a constant rate of approximately 5 micrograms per hour. This controlled release:
-
Total Delivered Dose:
- Over the 3-day period, the plaster delivers a total of 0.5 mg of scopolamine. This is calculated based on the constant release rate and the duration of application.
-
Design Rationale:
- The combination of a priming dose and controlled release is designed to:
- Provide rapid onset of action.
- Maintain therapeutic levels without peaks and troughs.
- Reduce the risk of side effects associated with variable drug levels.
- The combination of a priming dose and controlled release is designed to:
This sophisticated delivery system ensures that the scopolamine is released in a way that maximizes therapeutic benefit while minimizing potential adverse effects, making it an effective option for motion sickness and other indications.
Summary Table:
| Aspect | Details |
|---|---|
| Total Scopolamine | 1.5 mg reservoir |
| Priming Dose | 140 mcg in adhesive layer for rapid skin saturation and steady-state levels |
| Controlled Release | 5 mcg/hour for 3 days (total 0.5 mg delivered) |
| Design Benefits | Rapid onset, consistent blood levels, minimized side effects |
Need reliable transdermal drug delivery solutions?
Enokon specializes in bulk manufacturing of precision-engineered TTS plasters for pharmaceutical distributors and brands. Our expertise in controlled-release formulations ensures optimal therapeutic outcomes with minimized side effects. Contact our team today to discuss custom R&D or production needs!
